| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| ln Vitro |
Robinin (1-10 μg/ml, 24 h) has no obvious cytotoxicity in hPBMCs cells [1]. Robinin (6 μg/mL, 24 h) suppresses MCP 1, TNF-α, IL-6 in hPBMCs cells. Robinin (1 μM, 24 h) can inhibit the proliferation and migration of Mia-PACA2 and PANC-1 cells [2]. And ICAM-1 protein expression and TLR2, TLR4 mRNA levels, have anti-inflammatory actions [1]. 1]
|
|---|---|
| ln Vivo |
The combination of Robinin and Methotrexate (MTX) (50 mg/kg and 0.3 mg/kg, minimum, twice a week) has anti-inflammatory and anti-arthritic effects in an adjuvant arthritis model [3]. 50 mg/kg, wall, 10 days) can provide cardioprotection against doxorubicin-induced cardiotoxicity by modulating TGF-β1 signaling [4].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: hPBMC Tested Concentrations: 6 μg/mL Incubation Duration: 24 h Experimental Results: Inhibits the up-regulated expression of MCP 1, TNF-α, IL-6 and ICAM-1, and has anti-inflammatory properties. Cell viability assay[1] Cell Types: hPBMC Tested Concentrations: 1 μg/mL, 2 μg/mL, 4 μg/mL, 6 μg/mL, 8 μg/mL, 10 μg/mL Incubation Duration: 24 h Experimental Results: Concentration from 1μg/ml-10μg/ml has no obvious cytotoxicity to hPBMCs. RT-PCR[1] Cell Types: hPBMCs Tested Concentrations: 1 μg/mL, 2 μg/mL, 4 μg/mL, 6 μg/mL, 8 μg/mL, 10 μg/mL Incubation Duration: 24 h Experimental Results: Inhibition of TLR2 and TLR4 expression was upregulated. Cell proliferation assay [2] Cell Types: Mia-PACA2 and PANC-1 Tested Concentrations: 1 μM Incubation Duration: 24 h Experimental Results: Cell proliferation was inhibited. Cell migration assay[2] Cell Types: Mia-PACA2 and PANC-1 Tested Concentrations: 1 μM Incubation Duration: 24 hrs (hours) Experimental Results: diminished cell migration area |
| Animal Protocol |
Animal/Disease Models: Adjuvant arthritis mouse model [3]
Doses: 50 mg/kg Robinin and 0.3 mg/kg MTX Route of Administration: po (oral gavage) twice a week Experimental Results: Anti-inflammatory and anti-arthritic effects . Animal/Disease Models: Sprague Dawley rat model [4] Doses: 50 mg/kg Robinin for 10 days Route of Administration: po (oral gavage) Experimental Results: Reduction of doxorubicin-induced cardiotoxic effects |
| References |
|
| Additional Infomation |
Robinin is a glycosyloxyflavone that is kaempherol substituted by a 6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-galactopyranosyl residue at position 3 and a 6-deoxy-alpha-L-mannopyranosyl residue at position 7 via a glycosidic linkage. It has a role as a plant metabolite. It is a glycosyloxyflavone and a dihydroxyflavone. It is functionally related to a kaempferol.
Robinin has been reported in Glycine max, Trifolium ambiguum, and other organisms with data available. |
| Molecular Formula |
C33H40O19
|
|---|---|
| Molecular Weight |
740.66
|
| Exact Mass |
740.216
|
| CAS # |
301-19-9
|
| PubChem CID |
5281693
|
| Appearance |
White to yellow solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
1064.4±65.0 °C at 760 mmHg
|
| Melting Point |
194-195ºC
|
| Flash Point |
335.7±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.728
|
| LogP |
0.89
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
52
|
| Complexity |
1260
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
O1[C@]([H])([C@@]([H])([C@]([H])([C@]([H])([C@@]1([H])C([H])([H])O[C@@]1([H])[C@@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])[H])O1)O[H])O[H])O[H])O[H])O[H])O[H])OC1C(C2=C(C([H])=C(C([H])=C2OC=1C1C([H])=C([H])C(=C([H])C=1[H])O[H])O[C@@]1([H])[C@@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])[H])O1)O[H])O[H])O[H])O[H])=O
|
| InChi Key |
PEFASEPMJYRQBW-HKWQTAEVSA-N
|
| InChi Code |
InChI=1S/C33H40O19/c1-10-19(36)23(40)26(43)31(47-10)46-9-17-21(38)25(42)28(45)33(51-17)52-30-22(39)18-15(35)7-14(49-32-27(44)24(41)20(37)11(2)48-32)8-16(18)50-29(30)12-3-5-13(34)6-4-12/h3-8,10-11,17,19-21,23-28,31-38,40-45H,9H2,1-2H3/t10-,11-,17+,19-,20-,21-,23+,24+,25-,26+,27+,28+,31+,32-,33-/m0/s1
|
| Chemical Name |
5-hydroxy-2-(4-hydroxyphenyl)-7-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
|
| Synonyms |
EINECS 206-113-3 NSC 9222 Robinin UNII-75RT1VGM60Kaempferol-3-O-gal-rham-7-O-rham Kaempferol-3-O-robinoside-7-O-rhamnoside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~337.54 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (2.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3501 mL | 6.7507 mL | 13.5015 mL | |
| 5 mM | 0.2700 mL | 1.3501 mL | 2.7003 mL | |
| 10 mM | 0.1350 mL | 0.6751 mL | 1.3501 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
